All lobbying filings

Federal Street Strategies, LLC

Federal Street Strategies, LLC filed a Q3 report for Abbvie, Inc. on October 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Abbvie, Inc. · Biopharmaceutical Research & Development Company.

As filed: FEDERAL STREET STRATEGIES, LLC for ABBVIE, INC.

All filings by Federal Street Strategies, LLC · Everything Abbvie, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 4

PAUL BRATHWAITE

Previously held: Executive Director, Congressional Black Caucus; Deputy Assistant Secretary, ESA, U.S. Department of Labor; Special Assistant to the Secretary, U.S. Department of Labor.
VEN NERALLA New on this filing

Previously held: Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff, U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep. Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio; Senior Advisor, USDA; OPP; and MCC.
STACEY LEAVANDOSKY New on this filing

Previously held: Chief of Staff, U.S. Representative Zoe Lofgren; Senior Advisor, Committee on Science, Space & Technology; Senior Advisor, Committee on House Administration; Executive Director, California Democratic Congressional Delegation
KAADE WALLACE New on this filing

Previously held: Legislative Correspondent, U.S. Senator Amy Klobuchar; Staff Assistant, U.S. Representative Betty McCollum

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the budget and appropriations process Issues related to the treatment of vitiligo

Medicare/Medicaid

Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the budget and appropriations process

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.